Sign In
Buy HR
Healthcare Realty Trust Earnings Calls
| Release date | Apr 30, 2026 |
| EPS estimate | $0.390 |
| EPS actual | $0.410 |
| EPS Surprise | 5.13% |
| Revenue estimate | 283.741M |
| Revenue actual | 278.99M |
| Revenue Surprise | -1.67% |
| Release date | Feb 12, 2026 |
| EPS estimate | $0.400 |
| EPS actual | $0.400 |
| Revenue estimate | 285.297M |
| Revenue actual | 286.303M |
| Revenue Surprise | 0.352% |
| Release date | Oct 30, 2025 |
| EPS estimate | $0.400 |
| EPS actual | $0.410 |
| EPS Surprise | 2.50% |
| Revenue estimate | 285.86M |
| Revenue actual | 297.765M |
| Revenue Surprise | 4.16% |
| Release date | Jul 31, 2025 |
| EPS estimate | $0.400 |
| EPS actual | $0.410 |
| EPS Surprise | 2.50% |
| Revenue estimate | 292.314M |
| Revenue actual | 297.502M |
| Revenue Surprise | 1.77% |
Last 4 Quarters for Healthcare Realty Trust
Below you can see how HR performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 31, 2025 |
| Price on release | $15.36 |
| EPS estimate | $0.400 |
| EPS actual | $0.410 |
| EPS surprise | 2.50% |
| Date | Price |
|---|---|
| Jul 25, 2025 | $16.12 |
| Jul 28, 2025 | $15.66 |
| Jul 29, 2025 | $15.84 |
| Jul 30, 2025 | $15.56 |
| Jul 31, 2025 | $15.36 |
| Aug 01, 2025 | $16.54 |
| Aug 04, 2025 | $16.97 |
| Aug 05, 2025 | $16.95 |
| Aug 06, 2025 | $16.87 |
| 4 days before | -4.71% |
| 4 days after | 9.83% |
| On release day | 7.68% |
| Change in period | 4.65% |
| Release date | Oct 30, 2025 |
| Price on release | $17.76 |
| EPS estimate | $0.400 |
| EPS actual | $0.410 |
| EPS surprise | 2.50% |
| Date | Price |
|---|---|
| Oct 24, 2025 | $18.66 |
| Oct 27, 2025 | $18.67 |
| Oct 28, 2025 | $17.93 |
| Oct 29, 2025 | $17.75 |
| Oct 30, 2025 | $17.76 |
| Oct 31, 2025 | $17.72 |
| Nov 03, 2025 | $17.63 |
| Nov 04, 2025 | $17.61 |
| Nov 05, 2025 | $17.93 |
| 4 days before | -4.82% |
| 4 days after | 0.96% |
| On release day | -0.225% |
| Change in period | -3.91% |
| Release date | Feb 12, 2026 |
| Price on release | $17.49 |
| EPS estimate | $0.400 |
| EPS actual | $0.400 |
| Date | Price |
|---|---|
| Feb 06, 2026 | $16.92 |
| Feb 09, 2026 | $17.13 |
| Feb 10, 2026 | $17.36 |
| Feb 11, 2026 | $17.39 |
| Feb 12, 2026 | $17.49 |
| Feb 13, 2026 | $17.96 |
| Feb 17, 2026 | $18.53 |
| Feb 18, 2026 | $18.03 |
| Feb 19, 2026 | $18.09 |
| 4 days before | 3.37% |
| 4 days after | 3.43% |
| On release day | 2.69% |
| Change in period | 6.91% |
| Release date | Apr 30, 2026 |
| Price on release | $18.70 |
| EPS estimate | $0.390 |
| EPS actual | $0.410 |
| EPS surprise | 5.13% |
| Date | Price |
|---|---|
| Apr 24, 2026 | $18.72 |
| Apr 27, 2026 | $18.38 |
| Apr 28, 2026 | $18.59 |
| Apr 29, 2026 | $18.46 |
| Apr 30, 2026 | $18.70 |
| May 01, 2026 | $19.25 |
| May 04, 2026 | $19.58 |
| May 05, 2026 | $19.92 |
| May 06, 2026 | $20.24 |
| 4 days before | -0.107% |
| 4 days after | 8.24% |
| On release day | 2.91% |
| Change in period | 8.12% |
Healthcare Realty Trust Earnings Call Transcript Summary of Q1 2026
Healthcare Realty reported a strong Q1 2026, beating expectations and raising guidance. Key operational highlights: record leasing (2+ million sq ft), same-store NOI growth of ~6.9% (a company high), same-store occupancy up 110 bps to 92.3%, total portfolio occupancy 90.5%, tenant retention 93.5%, and average annual escalators of ~3%+. Capital allocation actions included $100M of share repurchases YTD, a pro rata $18M JV acquisition, and $56M of new redevelopment starts (including a $25M Boston project). The company announced a fully committed $400M unsecured delayed-draw term loan (expected to close in May) to help repay a $600M bond in late July/August and preserve liquidity (~$1B remaining after the transaction). Management reiterated a disciplined capital allocation framework (buybacks, JVs, redevelopments) and said organic earnings growth is tracking above 5% excluding prior-year portfolio optimization dilution. Guidance was raised modestly: normalized FFO revised to $1.59–$1.65 (midpoint $1.62) and same-store cash NOI growth to 3.75%–4.75%. Management emphasized execution risk remains but they are tracking ahead of their 3-year plan early in the rollout.
